Iboga and N,N-DMT are not versions of the same thing. Iboga is a whole-plant ceremony from the Tabernanthe ibogashrub — active for 12–24 hours, rooted in the Bwiti tradition of Central Africa. N,N-DMT is a single tryptamine compound, active for 5–20 minutes when smoked. Their mechanisms differ. Their durations differ by an order of magnitude. Their clinical evidence is at entirely different stages of development. The question of which is “stronger” or “deeper” does not map onto what each compound actually does.
In short: Iboga contains more than 30 alkaloids — the most studied being ibogaine — which act on opioid receptors, the serotonin transporter, NMDA receptors, and appear to trigger release of glial-derived neurotrophic factor (GDNF), a protein linked to neuroplasticity. N,N-DMT binds primarily to 5-HT2A serotonin receptors and produces its effects within minutes of inhalation. Different mechanisms, different durations, different candidate profiles.
What Iboga Is
Iboga is a shrub native to Central Africa — Gabon, Cameroon, and the Republic of Congo. The Bwiti tradition has used its root bark for centuries in initiation and healing ceremonies. The root bark contains more than 30 alkaloids, of which ibogaine is the most studied. The whole-plant preparation produces a different experience than isolated ibogaine — the full alkaloid profile modifies the ibogaine effect in ways the isolated compound does not replicate.
Ibogaine acts on multiple receptor systems simultaneously. It binds to mu- and kappa-opioid receptors, inhibits the serotonin transporter, blocks NMDA receptors, and appears to trigger release of glial-derived neurotrophic factor (GDNF) — a protein associated with neuroplasticity that is markedly reduced in addiction-affected dopamine pathways. This multi-receptor profile is why ibogaine's effects do not cleanly resemble any other compound.
The active experience runs 12–24 hours. The recovery period is 2–3 days. Noribogaine — the primary metabolite — remains active in the body for weeks to months after a single ceremony. That extended window is where much of the clinical interest in ibogaine's addiction and trauma effects sits.
The internal experience is not visually elaborate in the way N,N-DMT is described. Participants report an experience that is directional — confrontational with memory, pattern, and the sources of difficulty. What the medicine shows is not selected by the participant.
What DMT Is — and Which One
The label “DMT” most commonly refers to N,N-dimethyltryptamine, a tryptamine compound found in many plants and produced in trace amounts endogenously in mammals. When smoked or vaporised, N,N-DMT is active for 5–20 minutes. It binds primarily to 5-HT2A serotonin receptors and produces intense perceptual experiences — complex visual geometry, apparent entities, a sense of displacement into a separate space — that users consistently describe as distinct from anything produced by other compounds.
N,N-DMT is also the active compound in ayahuasca, paired with monoamine oxidase inhibitors (MAOIs) that prevent its breakdown in the digestive tract and extend the experience to 4–6 hours. The extended form has a different character than the smoked form, but the core mechanism — 5-HT2A binding — is the same.
Ibogaine is an indole alkaloid, but it does not bind to 5-HT2A in the way N,N-DMT does. The visual character associated with DMT experiences is not what iboga produces. People who come to iboga with prior N,N-DMT experience and expect similar perceptual elaboration find something different — an experience that is inward rather than outward, addressed to specific content rather than generated scenery, and running for 12–24 hours rather than 15 minutes.
If you are trying to understand how iboga compares to other plant medicines, the iboga and ayahuasca comparison covers the overlap between the Amazonian and Bwiti traditions in more detail.
How 5-MeO-DMT Differs From Both
5-MeO-DMT is a related but pharmacologically distinct compound. The “5-MeO” prefix matters — 5-methoxy-N,N-dimethyltryptamine acts primarily on 5-HT1A receptors rather than 5-HT2A. The result is not a visually elaborate experience. It is more consistently described as a dissolution of the sense of self — not landscapes or entities, but the apparent obliteration of both observer and observed — active for 20–45 minutes.
For anyone arriving with N,N-DMT experience, 5-MeO-DMT is not a larger dose of the same thing. The receptor distinction produces a qualitatively different experience. The shared label “DMT” is a chemical scaffold description, not a description of a shared effect.
Transcend Center works with iboga ceremony and 5-MeO-DMT ceremony. Neither is N,N-DMT. The distinction matters practically because people who arrive expecting N,N-DMT-like experiences — brief, intensely visual, with a sense of dimensional travel — are consistently surprised by what iboga and 5-MeO-DMT actually produce.
What the Evidence Shows
The clinical evidence for ibogaine is concentrated in two areas: opioid use disorder and trauma. A 2023 study published in Nature Medicine followed 30 special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression. One month after ibogaine treatment, the group showed an average 88% reduction in PTSD symptoms, 87% reduction in depression symptoms, and 81% reduction in anxiety symptoms. Conventional antidepressant research considers a 50% reduction in depression scores a strong response.
Following that publication, the Texas state legislature allocated $50 million USD to clinical ibogaine trials across UTMB, UTHealth Houston, Texas A&M, and Baylor University — funded through ongoing psychedelic research initiatives. This is not fringe medicine. It is a subject of active clinical investigation at major research universities.
The clinical evidence for N,N-DMT as a therapeutic agent is at an earlier stage. Research organisations have active interest in the mechanism, and the field is developing. But the accumulated trial record for addiction and trauma treatment does not yet exist in the way it does for ibogaine, which has been observed clinically since the 1960s. Comparing the two as therapeutic options is comparing a compound with decades of clinical observation against one being actively characterised.
Iboga is not a cure for addiction. It is a neurological reset — a window during which craving is reduced and new patterns are more possible. What happens during that window depends on what the person does with it. Iboga ceremony followed by a return to the same environment, relationships, and unaddressed conditions produces relapse. This is not a caveat. It is the condition under which results hold.
The most consistent observation among practitioners is that iboga does not deliver what people hope for — it delivers what they need, which is often not the same thing. People who found N,N-DMT remarkable and expect iboga to be the next thing on that spectrum regularly find it does not occupy that spectrum. Not because iboga is less. Because iboga is not on the same axis.
Who Is Not a Candidate for Iboga
This is not a minor qualification. Ibogaine prolongs the QT interval — a measurable effect on the heart's electrical cycle. For people with pre-existing cardiac conditions, this is an absolute contraindication, not a risk factor to weigh against potential benefit.
People who should not pursue iboga ceremony:
- Anyone with QT prolongation, a significant cardiac arrhythmia, or a recent myocardial infarction
- Anyone with severe liver or kidney disease
- Anyone with active psychosis or a schizophrenia spectrum disorder
- Anyone currently taking SSRIs or SNRIs — a supervised taper is required before ceremony can be considered
- Anyone on methadone — a specific transition protocol is required, not a standard taper
- Anyone on lithium or certain other psychiatric medications
- Anyone who is pregnant
Medical screening — a 12-lead EKG, blood panel covering liver and kidney function, and a full medication review — is required for every applicant. No ceremony date is confirmed before that screening is complete. The ibogaine contraindications page covers each item in this list in detail.
N,N-DMT does not carry ibogaine's cardiac risk profile. This is a factual difference between the two compounds. The screening requirement exists because the risk is real, and skipping it does not make the risk go away.
Is This Right for You?
The more useful question is not which compound is more intense — it is whether ibogaine's documented mechanism addresses what you are specifically trying to work with. If the answer involves opioid dependence, treatment-resistant PTSD, or depression that has not responded to conventional approaches, ibogaine has clinical evidence for those conditions that N,N-DMT currently does not.
If you have a cardiac condition, are on SSRIs or SNRIs, or have a schizophrenia spectrum diagnosis, iboga ceremony is not the right direction. The FAQ covers the most common questions about candidacy and screening. If you want to understand whether iboga is appropriate for your specific situation, submit an application — the intake conversation is how that question gets answered. Every application receives a personal response within 2–3 business days.
Integration is part of every programme. The integration page explains how the period after ceremony is structured and why it matters as much as the ceremony itself. Ceremony opens the window. Integration determines what is done while it is open.
You can also reach Jake directly at jake.nylund@gmail.com.